Michael Gregory Kurilla, M.D., Ph.D., will direct the NCATS Division of Clinical Innovation beginning Dec. 10, 2017. Kurilla's new role will include leading the Clinical and Translational Science Awards (CTSA) Program, which supports innovative solutions that advance the efficiency, quality and impact of translational science with the ultimate goal of getting more treatments to more patients more quickly. As the largest NIH initiative, the CTSA Program supports a national network of medical research institutions that work together to tackle system-wide scientific and operational problems in clinical and translational research that no one team can overcome.
Kurilla currently serves as director of the Office of BioDefense, Research Resources and Translational Research at NIH's National Institute of Allergy and Infectious Diseases (NIAID), where he also has been involved with biodefense product development. Prior to joining NIAID in 2003, Kurilla was an associate director for infectious diseases at Wyeth. He also worked at Dupont in antimicrobials, and on molecular pathology at the University of Virginia Health Sciences Center.